Potential of immuno-oncology therapies to selectively identify and attack the cancer cells which reduces the side effects is intended to take the global market for immuno-oncology to a new high in the coming future. Immuno-oncology therapies target the immune system of the body and not the tumor, by activating immune system to recognize the cancer cell and kill them by natural mechanism. These immuno-oncology therapies are becoming choice of therapy by oncologists as they provide long lasting effects such that the body can adapt to the changing behavior (resistance) of cancer cells toward immune system and improve the quality survival. Commercial immuno-oncology therapies are available against cancer types such as prostate cancer and melanoma and many other are under clinical studies. Some of the available immuno-oncology therapies include Zaltrap, Keytruda, Opdivo, Yervoy, Imlygic, Zyclara and others. Cancer treatment vaccines are currently being developed which can enhance the immune system’s response to tumor cell. Some of the FDA approved cancer treatment vaccines include Sipuleucel-T, bacillus Calmette-Guérin (BCG) etc.
A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/11329
Effective mechanism of immuno-oncology therapies for the patient with poor prognosis is expected to drive the growth of immuno-oncology market. The evidences from clinical trials reveals that the effects of immuno-oncology therapies on cancer cells would last for a longer time by preparing the immune system to fight against cancer cells even after the reduction in tumor cells. Additionally the side-effects associated with immuno-oncology therapies are limited as compared to many other cancer therapies, which creates a positive impact on the growth of immuno-oncology market. The restraining factors for the immuno-oncology therapies market are high cost of treatment, lack of awareness and slower pipeline development
The global immuno-oncology market has been classified on the basis of product type, end user and geography.
Based on product type, the global immuno-oncology market is segmented as follows:
- Monoclonal Antibodies (mAb)
- Antibody Drug Conjugates
- Cancer Treatment Vaccines
- Chimeric Antigen Receptor (CAR) T-Cell Therapies
- Interferon and Cytokine therapies
- PD-1/PD-L1 inhibitors
Based on end user, the global global immuno-oncology market is segmented as follows:
- Cancer Research Centers and Institutes
Extensive scope of immuno-oncology agents in various cancer treatments would provide maximum share to immuno-oncology treatment in overall cancer drug market during the forecast period. This lucrative opportunities in immuno-oncology treatment would provide boost to the product development during the forecast period. The slower pace of research and development activities and capital intense investment in manufacturing are the factors extending the commercialization of immuno-oncology therapies. However, lesser side effects associated with immunological treatments and better efficacy is expecting to get positive response from the cancer specialists after commercialization of immuno-oncology therapies.
Geographically, the global Immuno-oncology therapies market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America and Europe are the lucrative regions for immuno-oncology market due to their potential to invest the huge amount of money in the development of immuno-oncology therapies and availability of better reimbursement policies. Moreover, affordability for the cost of treatment is also high in North America and Europe. The global immuno-oncology market is expected to grow during the forecast period due to increasing investment by multinational companies in the cancer research
Some of the key players in global immuno-oncology market are Seattle Genetics, Inc., Genentech, Inc., F. Hoffmann-La Roche Ltd., Eisai Co. Ltd., Amgen Inc., Bayer AG, Sanofi Aventis LLC., Merck & Co., Inc., Bristol-Myers Squibb Company, Dendreon Corporation and others. The global immuno-oncology market is expected to grow during the forecast period due to increasing investment by multinational companies in the cancer research.
To View TOC of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/toc/11329
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, type of product and applications.
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.
Persistence Market Research Pvt. Ltd
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353